No abstract available.
Immunoenzyme Techniques*

No abstract available.
Fluoroimmunoassay* ; Immunoenzyme Techniques*

338 subjects at the age of 17-49 were undergone EIA test. Results showed an increasing trend in Chlamydia trachomatis infection. Clinical manifestations were not detected. The incidence is highest at the age of 17-26 (14.68%), 17-36 (10.67%). In the groups of genital tract inflamation, of uterine neck, of vaginitis the incidence reaches 2.7%, 12.71% and 12.50% respectively
Chlamydia trachomatis ; Immunoenzyme Techniques ; Women

No abstract available.
Immunoenzyme Techniques* ; Mycobacterium tuberculosis* ; Mycobacterium*

At the summer workshop of the Korean Endocrine Society held in 2016, some examples of protein experiments were discussed in the session entitled “All about working with proteins.” In contrast to what the title suggested, it was unrealistic to comprehensively discuss all protein analytical methods. Therefore, the goal was to outline protein experimental techniques that are useful in research or in bench work. In conversations with clinicians, however, I have always felt that researchers who do not engage in bench science have different demands than those who do. Protein research tools that are useful in bench science may not be very useful or effective in the diagnostic field. In this paper, I provide a general summary of the protein analytical methods that are used in basic scientific research, and describe how they can be applied in the diagnostic field.
Chromatography ; Education ; Immunoenzyme Techniques ; Methods* ; Molecular Imaging

The aim of this study was to evaluate domestic enzyme immunoassay(EIA) kit ?LG HCD 3.0?(LG) for the detection of antibody to hepatitis C virus(anti-HCV) in comparision with Axsym HCV version 3.0(Axsym), Cobas Core anti-HCV EIA(Cobas). Cobas kit shows better clear distinction between positive and negative by signal/cutoff ratio(S/C), but it also reveal relatively high false positive rate. The concordance rate of test results between LG and Axsym was 96.2%, between LG and Cobas was 95.5%, and total agreement between three EIA kit was 93.9%. LG were relative poor distinction between positive and negative results, but it could be applied clinically as a screening tool for hepatitis C in general population. The S/C of one false negative result by LG was 0.91, and false positive were less than 4.0, therefore we concluded it is necessary to confirm by immunoblotting assay when S/C were between 0.8 and 4.0.
Hepacivirus ; Hepatitis C ; Immunoblotting ; Immunoenzyme Techniques* ; Mass Screening

BACKGROUND: Generalized immune activation occurs early in the course of many infectious disease. Laboratory investigations have shown that immune activation can be quantified by the measurement of soluble immune activation products in serum. Soluble CD25, CD8, and CD4 are major immune activation products. Soluble CD8 and CD4 are indices of CD8+ T cell and CD4+T cell activity, respectively. OBJECTIVE: We estimated the concentrations of these molecules in patients with leprosy. METHODS: The study population consisted of 31 patients with tuberculoid leprosy and 71 patients with lepromatous leprosy(32 cases of M. leprae negative patients and 39 cases of M. leprae positive patients). Serum samples and clinical and laboratory data were collected form each patient and control. The levels of serum soluble CD25, CD8, and CD4 were measured by sandwich enzyme immunoassay. RESULTS: The levels of serum soluble CD25 were significantly raised in leprosy patients as compared to control and did not vary signficantly between tuberculoid and lepromatous leprosy. The soluble CD8 levels in the serum of patients with leprosy did not differ from the levels of the control. The levels of serum soluble CD4 were significantly decreased in the patients with lepromatous leprosy, but not in the patients with tuberculoid leprosy. However, there was no significant correlation between CD25, CD8, and cD4 and bacterial indices in patients with lepromatous leprosy. CONCLUSIONs: There data suggest that non-specific immune activation occurs the spectrum in leprosy, while CD4+ T cell activity is significantly decreased in patients with lepromatous leprosy.
Communicable Diseases ; Humans ; Immunoenzyme Techniques ; Leprosy* ; Leprosy, Lepromatous ; Leprosy, Tuberculoid

A 26 year old female presented complaining of a pea-sized nodule on her left lower eyelid for 10 years duration. Histopathological study showed several cysts in the dermis surrounded by secretory cells. The cysts were filled with decapitatory secretions. Positive staining with carcinoembrynic an tigen(CEA) was detected by immunoperoxidase technique. These clinical and histopathological findings suggest apocrine hidrocystoma developed on the left lower eyelid.
Adult ; Dermis ; Eyelids ; Female ; Hidrocystoma* ; Humans ; Immunoenzyme Techniques

BACKGROUND: The purpose of this study was to evaluate the newly improved third generation enzyme immunoassay kit, LG HCD 3.0TMB (LG Chemical Ltd., Korea) for the detection of antibodies for the hepatitis C virus. METHODS: The 1,068 clinical samples and 3 seroconversion panels were subjected to compare LG HCD 3.0TMB with Ortho HCV 3.0. The discordant clinical samples were confirmed by RT-PCR (Roche Amplicor HCV test) and RIBA (LG HCD confirm, Ortho RIBA HCV 3.0). Reproducibility was estimated using six samples with different anti-HCV levels for each assay. RESULTS: In clinical samples, concordance between LG HCD 3.0TMB and Ortho HCV 3.0 was 98.8% (1,055 of 1,068 tests) in the screening test. After a repeat test of 13 discordant samples, overall concordance was 99.3% (1,061 of 1,068 tests). In the seroconversion panel testing, the LG HCD 3.0TMB detected HCV antibodies earlier than the Ortho HCV 3.0 in one of the three panels. Results of both EIA assays were constant on the reproducibility test. CONCLUSIONS: Based on the good agreement with Ortho HCV 3.0 and superior seroconversion sensitivity, the LG HCD 3.0TMB assay appears to be suitable for detecting HCV antibodies in clinical laboratories.
Antibodies ; Hepacivirus ; Hepatitis C Antibodies* ; Immunoenzyme Techniques ; Mass Screening

BACKGROUND: The test for the anti-rubella IgM Ab (R-IgM) is important in early pregnancies because therapeutic termination may be considered depending on the results. METHODS: The subjects consisted of 52 pregnant women with positive or equivocal R-IgM by Cobas Core Anti-Rubella IgM EIA test (Roche, Basel, Swiss) between January 1997 and July 2000. Three different EIA methods such as the Enzygnost Anti-Rubella-virus/IgM test (DADE Behring, Marburg, Germany), the AxSYM Anti-Rubella IgM test (Abbott, USA), and the IMx Anti-Rubella IgM test (Abbott, USA) were simultaneously performed on 44 specimens as well as the Cobas Core Anti-Rubella IgM EIA test. RESULTS: Among 52 pregnancies, 9 (17%) experienced an artificial abortion due to positive or equivocal R-IgM result. The clinical symptoms associated with rubella infection were observed in 3 cases and the persistent R-IgM positivity was noted for more than 1 year in 4 cases. The concordance rate between 4 different EIAs was 41%. When performed with serial diluted pool and 3 sera, the results of Cobas Core were similar to those of AxSYM, IMx and Enzygnost. The R-IgM were detected one titre higher in diluted sera performed by IMx and Enzygnost than those of Cobas Core and AxSYM. CONCLUSIONS: For pregnancies with positive or equivocal R-IgM, it is recommended that results should be interpreted with caution, considering the possibilities, such as a persistent R-IgM response and discrepant R-IgM depending on the different EIA methods.
Female ; Humans ; Immunoenzyme Techniques* ; Immunoglobulin M* ; Pregnancy* ; Pregnant Women ; Rubella